CCDC169-SOHLH2

Across TCGA pan-cancer cohorts, CCDC169-SOHLH2 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of CCDC169-SOHLH2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where CCDC169-SOHLH2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CCDC169-SOHLH2 is over-expressed in tumor, although a few such as BLCA and COAD show the opposite, repressed pattern.

LUAD, BLCA, and COAD are the cancer types where CCDC169-SOHLH2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CCDC169-SOHLH2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	All	All	+0.090	<.001	7	view →
BLCA	Male	IV	−0.659	.001	4	view →
COAD	All	All	−0.102	.001	4	view →
BRCA	All	All	−0.067	<.001	4	view →
LUSC	All	All	+0.064	<.001	4	view →
THCA	All	All	−0.092	<.001	3	view →
KIRC	All	All	−0.063	.004	3	view →
READ	Female	All	−0.286	.011	2	view →
KIRP	Female	All	+0.254	.024	2	view →
KICH	Female	II,III,IV	−0.180	.003	2	view →
STAD	Female	III,IV	−0.065	.005	2	view →
ESCA	Male	All	−0.030	.013	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

CCDC169-SOHLH2–LUAD

Open the LUAD breakdown →